<div><em>In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy. </em></div>

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

<em>In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.&nbsp;</em>

S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

<div>Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.</div>

Science

Health & Fitness

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Share S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Sign up to save your podcasts

S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

S5 Ep4: Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

More shows like Treating Together

Planet Money

Interesting Times with Ross Douthat